Researchers aim to deliver GDNF into muscle cells using a viral vector to protect motor neurons and slow disease progression in a rat model of ALS. The study, led by Cedars-Sinai Regenerative Medicine Institute, could pave the way for a clinical trial if successful.
A new study suggests that gut microorganisms support the production of immune cells, which are essential for fighting infection. The research found that mice lacking gut microbes were more susceptible to bacterial infections, highlighting the importance of maintaining a healthy balance of gut microbes in our immune system.
Studies suggest that eye structure and function may reveal features of early-stage Alzheimer's disease, including changes in retinal pigment epithelial layer and choroidal layer thickness. Researchers hope to develop new diagnostic methods using the eye as a window to brain activity.
Researchers found that emotional stressors like anger can cause changes in the nervous system controlling heart rate, triggering microvascular coronary dysfunction more often in women than men. This condition can lead to heart attacks and other cardiac issues despite clear arteries.
Researchers have eradicated solid tumors in laboratory mice using a novel combination of two targeted agents that stimulate an immune response. This approach allows the patient's own tumor to act as a cancer vaccine, differing from traditional methods where the immune system is stimulated by administering a vaccine.
Researchers used innovative tools to detect a previously unknown gene mutation and initiate personalized drug treatment for a boy with uncontrollable seizures. Memantine was shown to have an effect in reducing seizure activity.
Researchers developed a unique, compact imaging device to 'light up' malignant brain tumors using scorpion venom protein and a laser. The system consists of a special camera and an imaging agent that targets cancer cells, enabling neurosurgeons to remove more tumor and spare healthy tissue during surgery.
A new Phase III clinical trial at Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute aims to provide kidney cancer patients with long-term control of their disease. The vaccine-based approach uses a patient's own immune system to fight the disease, potentially improving survival outcomes and quality of life.
Researchers at Cedars-Sinai will investigate the potential links between air pollution and brain cancer, with a focus on three pollutants: naphthalene, butadiene, and isoprene. The study aims to determine if prolonged exposure to these toxins can cause molecular changes in the brain that lead to brain tumor development.
A Cedars-Sinai research team led by Paul W. Noble is developing a novel approach to treat idiopathic pulmonary fibrosis, a disease that destroys the lungs and damages vital organs. The two-year study aims to build upon preliminary research and uncover the precise way normal lung stem cell repair occurs.
Cedars-Sinai researchers found that genetically targeting immune cells to overproduce ACE breaks down beta-amyloid plaque, preventing cognitive decline in laboratory mice. The study identifies a novel role for ACE in the clearance of beta-amyloid in brain blood vessels.
Researchers found that dormant prostate cancer cells can be reactivated by factors produced in inflammatory cells, such as RANKL. This discovery may allow for the development of new interventions to prevent disease progression and prolong survival.
A multicenter research team led by Cedars-Sinai neurologist Nancy Sicotte used a new automated technique to identify shrinkage of the right hippocampus in women with multiple sclerosis and depressive symptoms. The study found reduced size of the right hippocampus, while the left remained unchanged.
A Phase I clinical trial is underway to evaluate the safety and dosing of a personalized vaccine targeting cancer stem cells in patients with recurrent glioblastoma multiforme. The vaccine aims to boost the immune system's ability to recognize and destroy cancer cells, potentially leading to improved treatment outcomes.
Researchers aim to understand the causes of pregnancy complications in assisted reproductive technologies, as well as how hospital environments impact childbirth. The studies will investigate genetic and epigenetic factors and evaluate obstetrical resources to identify optimal levels of care.
Ueli Rutishauser, a young scientist at Cedars-Sinai, has made significant contributions to understanding the brain's role in learning, memory, and decision-making. His research has improved our understanding of autism and learning disorders, as well as the effects of epilepsy on the nervous system.
Researchers at Cedars-Sinai Medical Center have identified gene expression regulators, microRNAs, in normal and diabetic human corneas, which may contribute to stem cell and epithelial abnormalities. The study aims to accelerate healing and repair processes in damaged corneas to reverse diabetes-induced eye complications.
Scientists have discovered six proteins essential for cell-to-cell communication in the heart, regulating heartbeat synchronization and limiting heart attacks and strokes. The findings also suggest that mTOR inhibitors can be used to prevent erratic heart rhythms, offering a potential treatment for arrhythmias and heart failure.
Researchers at Cedars-Sinai identified immune system targets on cancer stem cells and created an experimental vaccine to attack them. The vaccine, which uses dendritic cells, was tested in lab mice and showed promise without causing side effects.
A new research study at Cedars-Sinai Medical Center is investigating the predictors, mechanisms for development, and persistence of post-treatment fatigue in breast cancer patients. The study will examine biological, behavioral, and social risk factors to identify women at high risk for fatigue.
The World Health Organization study reveals atrial fibrillation affects 33.5 million people worldwide, leading to significant healthcare burden and mortality rates, particularly in developing countries.
Researchers at Cedars-Sinai have discovered a 10-gene biomarker panel that can identify the aggressiveness of ovarian cancer, predict survival outcomes, and inform novel therapeutic strategies. The study suggests that this biomarker panel may have predictive value and biological relevance for treating patients with ovarian cancer.
Researchers at Cedars-Sinai Medical Center have developed a novel procedure to prepare human amniotic membrane for use as a scaffold for specialized stem cells, which may treat corneal diseases such as blindness. The new method promises to streamline clinical applications of cell therapies and accelerate research in this area.
A Phase I clinical trial found that eight out of 16 patients with glioblastoma multiforme survived longer than five years, with median overall survival at 38.4 months. The treatment used an ICT-107 vaccine to alert the immune system to cancer cells and activate a tumor-killing response.
Researchers recorded individual nerve cells in the amygdala of patients with high-functioning autism and found a specific type of neuron responding abnormally to the mouth region. The study provides new insights into mechanisms underlying autism symptoms and opens the door for further studies.
Researchers have identified large oncosomes as a potential indicator of patients with more aggressive, treatment-resistant disease. The study also found that microRNA in these vesicles can influence tumor progression.
A team of doctors and scientists at Cedars-Sinai Medical Center used stem cell technology to create neurons from patients' skin cells and block the damaging effects of a defective gene. The study provides proof of concept for a new therapeutic strategy, suggesting a potential future therapy for Lou Gehrig's disease.
A new blood test has been identified as a reliable biomarker for Irritable Bowel Syndrome (IBS), distinguishing it from Inflammatory Bowel Disease (IBD). The test targets high levels of vinculin antibodies in patients, offering a simple and effective diagnostic tool.
A new study found that only 12 out of 92 eligible patients received an implantable cardiac defibrillator after being medically evaluated. The majority who qualified did not receive the treatment, highlighting a need for further analysis to determine why this occurs.
A new observational study suggests that bioidentical hormones in transdermal patches may be associated with a lower risk of heart attack, while FDA-approved products may carry a slightly lower risk of stroke compared to synthetic hormones. The findings are inconclusive and require confirmation by randomized trials.
Researchers are identifying genetic biomarkers in patient blood samples to predict aggressive breast cancer progression. Large oncosomes, tumor-derived vesicles, may serve as valuable insights into disease progression.
A Cedars-Sinai researcher has been awarded $5.18 million to advance stem cell technologies in segmental bone defects. The team aims to develop a novel approach to treat the condition without grafting bone, using stem cells and ultrasound to deliver a bone-forming gene.
Researchers have developed a new nanoscale drug that can carry multiple weapons and target HER2-positive breast cancer cells from the inside. The therapy stimulates an antitumor immune response, blocks blood vessel formation, and slows tumor growth.
A study by Cedars-Sinai Medical Center's Movement Disorders Program identified variables that affect impedance in deep brain stimulation devices, which can alter patient outcomes. Regular clinic visits are crucial to ensure steady levels of stimulation and prevent side effects.
Researchers at Cedars-Sinai Medical Center have uncovered the crucial role of Caveolin-1 protein in prostate cancer tumor microenvironment. A decreased level of this protein in the stroma indicates worse prognosis and higher chance of disease relapse.
Researchers at Cedars-Sinai Medical Center are developing a new stem cell therapy approach to treat limbal epithelial stem cell deficiency, a common cause of corneal blindness. The goal is to create a corneal cell source for transplantation using induced pluripotent stem cells from patients' own eyes.
A long-term study of patients with hereditary dystonia found symptom severity dropped to less than 20% within two years after device implantation. Sixty-one percent were able to discontinue all medications and 91% could discontinue at least one class of drugs.
A $150,000 grant from Coalition Duchenne will fund a clinical trial investigating the use of cardiac stem cells to treat Duchenne muscular dystrophy patients with heart disease. The experimental therapy has shown promising results in regenerating healthy heart muscle and reducing damage caused by heart attacks.
Researchers have developed a device that captures and isolates potentially high-risk cancer cells, enabling doctors to access and identify cancerous cells in the bloodstream. This technology may revolutionize conventional biopsy practices and significantly advance personalized medicine.
A Cedars-Sinai study suggests that certain microorganisms in the gut may contribute to weight gain by allowing individuals to reap more calories from their food. The study found that people with high concentrations of methane and hydrogen gases in their breath had higher body mass indexes and body fat percentages.
Researchers found that two patients with severe dystonia experienced prolonged symptom relief despite interrupted deep brain stimulation therapy. The study suggests that younger brains and shorter disease duration may be more responsive to treatment.
A clinical trial combining brain cooling and clot-busting drug therapy has received FDA approval to expand from 50 to 400 participants. Brain cooling has been shown to reduce neurological damage after stroke, with potential benefits in saving lives and preventing neurological damage after heart attack.
Researchers found that stem cell therapy stimulates the heart's natural repair mechanism, boosting production of adult heart cells and recruitment of existing stem cells. The treatment enhances heart structure and function, with new muscle formed being functional and durable.
Cedars-Sinai researchers have successfully converted ordinary heart cells into pacemaker cells using a single gene, Tbx18. The new cells generate electrical impulses and are indistinguishable from native pacemaker cells, offering a potential alternative to electronic pacing devices.
A Cedars-Sinai physician-scientist is leading a research study on Charcot-Marie-Tooth disease, the most common inherited neurological disorder, using induced pluripotent stem cells. The goal of the study is to determine if personalized stem cell lines can be generated for individual patients and potentially cure the disease.
A study at Cedars-Sinai found that the common drug tadalafil reversed the effects of a biochemical chain in patients with Becker muscular dystrophy, improving blood flow and oxygenation. The researchers plan longer-term studies to determine if this strategy can slow the course of the disease.
Researchers found that VEGF-modified bone marrow stem cells sustain pancreatic recovery in a laboratory mouse model of insulin-dependent diabetes. The study provides new insights into mechanisms involved in regeneration of insulin-producing cells and offers evidence for using diabetic patients' own bone marrow as a source of treatment.
A recent study published in Diabetes Care found that Latinos are more vulnerable to fatty pancreas and Type 2 diabetes due to their ability to store excess fat in the pancreas. This can lead to a reduced capacity for insulin production, increasing the risk of developing the disease.
Researchers at Cedars-Sinai Heart Institute will study the cellular mechanisms behind an experimental stem cell therapy that regenerates healthy muscle in damaged hearts. The treatment has shown promising results, with a 50% reduction in scar size and improved cardiac regeneration.
High doses of vitamin B3 stimulate a specific gene to enhance white blood cells' ability to combat staph infections. The study found that vitamin B3 increased the body's immune system by up to 1,000 fold, killing staph bacteria in laboratory tests